Literature DB >> 30620275

One year in review 2018: gout.

Leonardo Punzi1, Anna Scanu2, Paolo Spinella3, Paola Galozzi2, Francesca Oliviero2.   

Abstract

Gout is the most common form of inflammatory arthropathy, and is associated with excruciating pain, major impairment of quality of life, and increased risk of comorbidities and mortality. Although gout has somehow been neglected by researchers and clinicians in the past, in more recent times there has been a renewed interest in this disease, which has led to major improvements in its management. This article reviews the new clinical and experimental evidence about gout that emerged in 2017 and in the first half of 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30620275

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Associaton of Retinol Binding Protein 4 (RBP4) Levels With Hyperuricemia: A Cross-Sectional Study in a Chinese Population.

Authors:  Guo-Bao Hong; Xiao-Fei Shao; Jia-Min Li; Qin Zhou; Xiao-Su Ke; Pei-Chun Gao; Xiao-Lin Li; Jing Ning; Hai-Shan Chen; Hua Xiao; Chong-Xiang Xiong; Hequn Zou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

2.  Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout.

Authors:  Chia-Chun Tseng; Man Chun Wong; Wei-Ting Liao; Chung-Jen Chen; Su-Chen Lee; Jeng-Hsien Yen; Shun-Jen Chang
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

3.  Anti-Gout Effects of the Medicinal Fungus Phellinus igniarius in Hyperuricaemia and Acute Gouty Arthritis Rat Models.

Authors:  Hongxing Li; Xinyue Zhang; Lili Gu; Qín Li; Yue Ju; Xuebin Zhou; Min Hu; Qīn Li
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

4.  Hypomethylation of the opioid receptor delta 1 gene combined with high opioid receptor delta 1 protein levels indicates increased risk of gout.

Authors:  Ying Ying; Xiaoke Li; Yong Chen
Journal:  J Clin Lab Anal       Date:  2022-07-31       Impact factor: 3.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.